Archive for the ‘Scientific & Biotech Conferences: Press Coverage’ Category

Translational Gene Editing – June 16-17, 2016 in Boston, MA by CHI, Westin Boston Waterfront, Boston, MA

Posted in CRISPR/Cas9 & Gene Editing, Scientific & Biotech Conferences: Press Coverage on December 15, 2015| Leave a Comment »

Translational Gene Editing – June 16-17, 2016 in Boston, MA by CHI, Westin Boston Waterfront, Boston, MA

Reporter: Aviva Lev-Ari, PhD, RN

 

Gene editing, particularly using the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system, is now being extensively used as a research and functional screening tool in drug discovery. Cambridge Healthtech Institute’s second annual conference on Translational Gene Editing will bring together experts from all aspects of preclinical research, from early target discovery to drug delivery, to talk about the progress being made in gene editing and how it’s being applied. Learn about ways in which CRISPR/Cas9 is being used to identify targets, create relevant cell lines and in vivo disease models, set up functional screens, and for targeted drug delivery. What can you do to overcome some of the inherent challenges with design, delivery and off-target effects associated with CRISPR/Cas9? Hear from experts in pharma/biotech, academic and government labs who will share their experiences leveraging the utility of gene editing for diverse applications, particularly in oncology and immunotherapy. PRELIMINARY AGENDA Gene Editing for Screening Pathways and Drug Targets CRISPR-Cas9 Whole Genome Screening: Going Where No Screen Has Gone Before Ralph Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center Parallel shRNA and CRISPR/Cas9 Screens Reveal Biology of Stress Pathways and Identify Novel Drug Targets Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University Cross-Species Synthetic Lethal Screens and Applications to Drug Discovery Norbert Perrimon, Ph.D., Professor, Department of Genetics, Harvard Medical School and Investigator, Howard Hughes Medical Institute Scouring the Non-Coding Genome by Saturating Edits Daniel E Bauer M.D., Ph.D., Assistant Professor of Pediatrics, Harvard Medical School and Staff Physician in Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Principal Faculty, Harvard Stem Cell Institute Building the CRISPR Toolbox Optimized sgRNA Libraries for Genetic Screens With CRISPR-Cas9 John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT Beyond Cas9: Discovering Single Effector CRISPR Tools Jonathan Gootenberg, Member, Laboratories of Dr. Aviv Regev and Dr. Feng Zhang, Department of Systems Biology, Harvard Medical School, and Broad Institute of Harvard and MIT CRISPR-Cas9 Genome Editing Improves Sub-cellular Localization Studies Netanya Y. Spencer, M.D., Ph.D., Research Fellow in Medicine, Joslin Diabetes Center, Harvard Medical School Improving Precision and Delivery Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing Daniel G. Anderson, Ph.D., Professor, Department of Chemical Engineering, Institute for Medical Engineering & Science, Harvard-MIT Division of Health Sciences & Technology and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology Understanding and Translating In vivo Findings Application of Genome Editing Tools to Model Human Genetics Findings in Drug Discovery Myung Shin, Ph.D., Principal Scientist, Biology-Discovery, Genetics and Pharmacogenomics, Merck Research Laboratories Translating CRISPR/Cas9 Into Novel Medicines Alexandra Glucksmann., Ph.D., COO, Editas Medicine Recommended Short Course* SC8: A Primer to Gene Editing: Tools and Application – Learn More Instructors: -John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT -Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University -Stephanie Mohr, Ph.D., Lecturer, Genetics & Director of the Drosophila RNAi Screening Center, Harvard Medical School – Claire Yanhui Hu, Ph.D, Senior Bioinformatician, Drosophila RNAi Screening Center, Department of Genetics, Harvard Medical School The course will help the novice understand the basics of how gene editing works, what tools are available for use and how those tools differ from each other. For the expert, this course will offer details on the CRISPR technology, how to set up CRISPR-based screens and complement it with existing RNAi-based screens using proper analysis and follow-up studies. The instructors will also cover the use of gene editing in drug discovery and disease modeling and best practices for design and workflows when working with other model systems, besides mammalian cells. *Separate Registration Required For questions or suggestions about the meeting, please contact: Tanuja Koppal, Ph.D. Conference Director Cambridge Healthtech Institute T: (+1) 973-525-4667 E: tkoppal@healthtech.com For sponsorship and exhibit sales information including sponsored podium presentations, contact: Joseph Vacca Associate Director, Business Development Cambridge Healthtech Institute T: (+1) 781-972-5431 E: jvacca@healthtech.com For more information visit WorldPreclinicalCongress.com/Gene-Editing

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Scientific & Biotech Conferences: Press Coverage, tagged Cancer 2016 World Medical Innovation Forum on December 2, 2015| Leave a Comment »

Marcela Valderrama Maus

2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston

 

ANNOUNCEMENT

Leaders in Pharmaceutical Business intelligence will cover in Real Time using Social Media this Event on CANCER Innovations

Aviva Lev-Ari, PhD, RN will be streaming LIVE from the Westin in Boston

worldmedicalinnovation.org

 

 

On behalf of Brigham and Women’s Hospital, Massachusetts General Hospital, and all of Partners HealthCare, we are pleased to invite you to the 2016 World Medial Innovation Forum. This unprecedented gathering will highlight the most promising approaches to diagnose, treat, and manage cancer and feature more than 100 speakers from throughout the top ranks of the global oncology community. For a complete list of our agenda and internationally recognized speakers, please visit the World Forum website.

UPDATED on 4/13/2016

2016 WORLD MEDICAL INNOVATION FORUM TO FEATURE INNOVATIONS ENHANCING PATIENT CARE FROM PREVENTION TO THE NEEDS OF LONG-TERM CANCER SURVIVORS

 

BOSTON – April 13, 2016 – Partners HealthCare today announced that the upcoming World Medical Innovation Forum™ will include a focus on patient care, ranging from discussions of the importance of cancer prevention and early detection and the innovations that are making it possible to the unique care requirements and new technology approaches to help survivors. The 2016 Forum, an annual collaboration and partnering event held in Boston on April 25-27, will focus on cancer. CEOs and senior company executives, top investors, policy experts, and Harvard scientists leading the charge in the fight against cancer will take the stage over the course of the three-day Forum for a series of sessions that will critically examine the innovations in and evolution of cancer care.

“Technological advances in diagnostics are beginning to make it possible to detect cancer at the earliest stages of the disease when treatment may be most effective,” said David Louis, MD, Pathologist-in-Chief, Massachusetts General Hospital and Benjamin Castleman Professor of Pathology, Harvard Medical School. “However, there have been many barriers to making these innovative tests widely available to patients, including the need for more research and development to ensure accuracy, better guidance to speed the regulatory process and new models to support their value and reimbursement. This Forum provides a space for us to learn about these exciting new diagnostic technologies and to collaborate on the scientific and economic challenges that preventative strategies and early cancer detection bring about.”

“Detecting cancer as early as possible in the developmental stage will help both patients and hospitals in terms of prognosis with possible cure or therapy regimens before the cancer has spread. It will also help avoid the economic burden typically associated with late-stage detection,” said Massimo Loda, MD, Senior Pathologist, Brigham and Women’s Hospital, Principal Investigator, Dana-Farber Cancer Institute, and Professor of Pathology, Harvard Medical School. “The technologies we are creating and pursuing are designed to detect and pursue cancer cells at the most vulnerable point in their development: the very beginning. The Forum will provide us with the opportunity to discuss those advances and learn of other new developments in a collaborative manner.”

The prevention of cancer and the development of new strategies to detect cancer precursors and early-stage malignancies when treatment may be most effective – clinically and financially – are critical research goals. The experts on the “Early Detection and Prevention of Cancer” panel will review powerful imaging modalities, single-cell analysis of the tumor microenvironment and next-generation cancer models. They will also discuss circulating tumor DNA testing to monitor response to treatment and emergence of cancer resistance-with the objective of early cancer diagnosis before symptoms appear. The panel will take place at 4:50 p.m. on Monday, April 25, 2016, in the Novartis Ballroom of The Westin Copley Hotel.

Panel participants include:

• Moderator: David Louis, MD, Pathologist-in-Chief, MGH and Benjamin Castleman Professor of Pathology, Harvard Medical School
• Andy Chan, MD, Program Director, Gastroenterology Training Program, MGH and Associate Professor of Medicine, Harvard Medical School
• William Hait, MD, PhD, Global Head, Janssen Research & Development
• Krishna Kumar, CEO, Emerging Businesses, Philips
• Massimo Loda, MD, Senior Pathologist, Principal Investigator, BWH, Dana-Farber and Professor, Department of Pathology, Harvard Medical School

“The number of people diagnosed with cancer is continuing to grow at an astounding rate and while new treatment advances are enabling more and more of these patients to survive, there is an increasing need for innovative tools and resources to address the changing needs of patients, their families and the health care system,” said Claire Thom, Pharm D, Senior Vice President, Global Oncology Development, Astellas.

Extraordinary treatment advances have turned many cancers from apparent death sentences into manageable chronic illnesses with extraordinary consequences for the entire health care system. In the United States, there are approximately 14 million cancer survivors, up from just three million four decades earlier. Those survivors have unique care requirements, that will put enormous stress on the system and calling out for new technology solutions. A program, titled “Surviving Cancer: New Realities, New Needs,” will discuss those requirements and the technologies and approaches that can help monitor, guide, and connect patients. The panel will take place at 4:00 p.m. on Tuesday, April 26, 2016, in the Takeda Ballroom of The Westin Copley Hotel.

Panel participants include:

• Moderator: Tim Ferris, MD, Senior Vice President of Population Health Management, Partners HealthCare
• Jani Ahonala, CEO, Noona Healthcare
• Don Dizon, MD, Clinical Co-Director, Gynecologic Oncology, Founder and Director, The Oncology Sexual Health Clinic, MGH and Associate Professor of Medicine, Harvard Medical School
• Ann Partridge, MD, Director, Adult Survivorship Program, Program for Young Women with Breast Cancer, Dana-Farber and Associate Professor of Medicine, Harvard Medical School
• Claire Thom, Pharm D, Senior Vice President, Global Oncology Development, Astellas

Sponsors of the Forum include Novartis, Bristol-Myers Squibb, Takeda Oncology, Amgen, Astellas, AstraZeneca, General Electric, Ipsen, MacDougall Biomedical Communications, McCall & Almy, Mintz Levin, Ropes & Gray, and Vertex. STAT is the exclusive media partner of the Forum.

About the World Medical Innovation Forum

The World Medical Innovation Forum is a global gathering of senior corporate, investor, and academic leaders. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together and its ability to improve patient lives.

For more information or to register, please go to www.worldmedicalinnovation.org.

About Partners HealthCare

Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners HealthCare is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.

 SOURCE

From: Kari Watson <contact@macbiocom.ccsend.com> on behalf of Kari Watson <wmif@macbiocom.com>

Reply-To: <wmif@macbiocom.com>

Date: Wednesday, April 13, 2016 at 10:59 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Medical Innovation Forum to Feature Innovations Enhancing Patient Care

 

Monica Bertagnolli, MD Chief, Division of Surgical Oncology, BWH Professor of Surgery, Harvard Medical School World Forum Co-Chair   Daniel Haber, MD, PhD Director, Cancer Center, MGH Isselbacher/Schwartz Professor of Oncology, Harvard Medical School World Forum Co-Chair

AGENDA

Updated on 4/13/2016

MONDAY, APRIL 25, 2016

 

7:00 am – 8:00 am
Ipsen Foyer

Continental Breakfast

7:00 am – 8:00 am
Ipsen Foyer

Registration Opens

8:00 am – 12:00 pm
Takeda Ballroom

First Look: The Next Wave of Cancer Breakthroughs

Highly creative young investigators describe their most promising commercially
related research. Rapid-fire presentations by two dozen early-career Harvard
Medical School faculty will highlight compelling new discoveries and insights that
will be the cancer care products of the future. These young stars from Brigham and
Women’s Hospital, Massachusetts General Hospital and Dana-Farber Cancer
Institute will each describe their work in highly organized 10-minute sessions. This
session will take place in the Takeda Ballroom. Presenters will be available
immediately following their talk in the third floor GE Foyer.

12:00 pm – 1:30 pm
Bristol-Myers Squibb Ballroom

Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare

Top Harvard Medical School faculty from Brigham and Women’s Hospital,
Massachusetts General Hospital and Dana-Farber Cancer Institute will host intimate
lunch discussions on developments in their field and their own research. These
internationally renowned leaders will engage on cutting edge research and new
trends in their clinical and research domain. Seating is reserved based on prior
registration. Please check at registration to find if there is open table availability.

A complete list of table hosts and topics is available here: http://worldmedicalinnovation.org/highlights/

1:45 pm – 1:55 pm
Novartis Ballroom

Forum Opening

Introduction by: Anne Klibanski, MD

• Chief Academic Officer, Partners HealthCare
• Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

David Torchiana, MD

• CEO, Partners HealthCare

1:55 pm – 2:20 pm
Novartis Ballroom

A War or Moonshot: Where Do We Stand?

Forum Co-Chairs Dr. Bertagnolli and Haber provide perspectives on the coming era
of cancer research and care.

Moderator: Nancy Snyderman, MD

• Medical Advisor, GE Healthymagination

Monica Bertagnolli, MD

• Chief, Division of Surgical Oncology, Brigham and Women’s Hospital
• Professor of Surgery, Harvard Medical School

Daniel Haber, MD, PhD

• Director, MGH Cancer Center
• Kurt J. Isselbacher /Peter D. Schwartz Professor of Oncology, Harvard Medical School

2:20 pm – 3:10 pm
Novartis Ballroom

Creating a Disruptive Cancer Pipeline

Some companies characterize creating a successful pipeline of disruptive cancer
therapies as an engineering challenge, others describe arranging building blocks or
integrating capabilities from the marketplace – for many it is all of the above.
Considerations include discovering novel targets, novel single agent drugs and
emerging novel mechanisms, new pathways and/or mechanisms of action, new
molecular entities and technology acquisition strategies, among others. The panel,
corporate officers, investors and academic experts pulls back the curtain to discuss
the considerations in pipeline development, the tradeoffs and what it takes to
maintain success over time.

Moderator: Robert Tepper, MD

• Partner, Third Rock Ventures
• Adjunct Professor, Harvard Medical School

James Bradner, MD

• President, Novartis Institutes for BioMedical Research

George Demetri, MD

• Director, Center for Sarcoma and Bone Oncology, Senior Vice President for Experimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute

Steve Fawell, PhD

• VP, Head Oncology iScience, AstraZeneca

Keith Flaherty, MD

• Director, Clinical Research, MGH Cancer Center
• Associate Professor of Medicine, Harvard Medical School

Sean Harper, MD

• Executive Vice President, Research and Development, Amgen

3:10 pm – 4:00 pm
Novartis Ballroom

Curative Therapies: The Economics of Game Changing Science

Novel, potentially curative, cancer therapies are coming to market. Recent
experience in Hepatitis C therapy raises the question as to whether a new approach
is needed to design a pricing model that better balances resulting cost pressure
across the delivery system. While most acknowledge systemic cost effectiveness
curative therapies also present many challenges to payers – e.g. a spike in patient
volume and cost as these therapies are introduced. A broad ranging dialogue
has emerged in the cancer community that includes incorporating cost
effectiveness as part of the regulatory approval, shifting incentives for oncologists,
increasing emphasis on early detection, integrating billing codes, bundled
payments and management fees and many others. The panel with top executives
from the pharma, foundation, pharmacy and provider sectors will share insights on
this crucially important topic.

Introduction by: Gregg Meyer, MD

• Chief Clinical Officer, Partners Healthcare System

Moderator: Sue Siegel

• CEO, GE Ventures and Healthymagination

Troyen Brennan, MD

• Executive Vice President and CMO, CVS Health

Paul Hudson

• President, AstraZeneca US
• Executive Vice President, AstraZeneca North America

Betsy Nabel, MD

• President, Brigham and Women’s Hospital
• Professor of Medicine, Harvard Medical School

Gary Reedy

• CEO, American Cancer Society

Peter Slavin, MD

• President, Massachusetts General Hospital
• Professor of Healthcare Policy, Harvard Medical School

4:00 pm – 4:50 pm
Novartis Ballroom

Winning Portfolio Strategy

The many considerations involved in managing a cancer portfolio are among the
most important for company vitality and also play a principal role in determining
the breadth and rate that new therapies reach patients. Considerations include
drug categories (current or potential), use of approved drugs on new tumor
types, product life extension, concentrating on call point strengths vs broadening
into new cancers, technology category strength – e.g. small molecule vs emerging
ones like CAR-T, product lifecycle status, competitive agents, possible portfolio
swaps (e.g. NVS/GSK) and shareholder scrutiny . Panel members from the highest
ranks of the industry — large and emerging companies — will discuss their strategic
approach to balancing considerations they can influence and those that they can’t.

Moderator: Thomas Lynch, MD

• CEO, Mass General Physician’s Organization

Francis Cuss, MD

• Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb

Peter Lebowitz, MD, PhD

• Global Therapeutic Area Head, Oncology, Janssen R&D

Briggs Morrison, MD

• CEO, Syndax Pharmaceuticals

Alessandro Riva, MD

• Global Head, Oncology Development and Medical Affairs, Novartis Oncology

Phil Rowlands, PhD

• Interim Head, Oncology, Therapeutic Area Unit, Takeda

4:50 pm – 5:40 pm
Novartis Ballroom

Early Detection and Prevention of Cancer

The prevention of cancer and the development of new strategies to detect cancer
precursors and early-stage malignancies when treatment may be most effective
– clinically and financially — are critical research goals. Our panel of experts reviews
powerful imaging modalities, single-cell analysis of the tumor microenvironment
and next-generation cancer models. Circulating tumor DNA testing to monitor
response to treatment and emergence of cancer resistance—with the objective of
early cancer diagnosis before symptoms appear—will also be detailed.

Moderator: David Louis, MD

• Pathologist-in-Chief, Massachusetts General Hospital
• Benjamin Castleman Professor of Pathology, Harvard Medical School

Andy Chan, MD

• Program Director, Gastroenterology Training Program, Massachusetts General Hospital
• Associate Professor of Medicine, Harvard Medical School

William Hait, MD, PhD

• Global Head, Janssen Research & Development

Krishna Kumar

• CEO, Emerging Businesses, Philips

Massimo Loda, MD

• Senior Pathologist, Principal Investigator, Brigham and Women’s Hospital, Dana-Farber Cancer Institute
• Professor, Department of Pathology, Harvard Medical School

5:45 pm – 5:55 pm
Novartis Ballroom

Innovation Break: Announcing the C³ Prize from Astellas Oncology and the World Medical Innovation Forum

5:55 pm – 6:45 pm
Takeda Ballroom

Ropes & Gray Welcome Reception

6:45 pm – 8:00 pm
Bristol-Myers Squibb Ballroom

Ropes & Gray Dinner Program – Fireside Chat: Richard Gonzalez, CEO, AbbVie

Introduction by: Ed Lawrence

• Retired Partner, Ropes & Gray

Moderator: Nancy Snyderman, MD

• Medical Advisor, GE Healthymagination

Richard Gonzalez

• CEO, AbbVie

TUESDAY, APRIL 26, 2016

 

7:30 am – 8:30 am
Ipsen Foyer

Continental Breakfast

8:15 am – 9:05 am
Novartis Ballroom

Global Cancer Markets

Cancer causes 1 in 7 deaths worldwide. If rates don’t change, the global cancer
burden is expected to increase from 14 million new cases and 8 million cancer
related deaths worldwide to 22 million cases and 13 million deaths by 2030. The
panel will discuss how approaches to deliver innovative technologies differ in
different international markets, what the respective drivers are, as well as
requirements and challenges. Expert panelists from leading international
companies and key governmental entities, including the famed NICE from the UK
NHS, will consider strategies and key trends.

Moderator: Sheila Dharmarajan

• Head of Business Development, Zelnick Media Capital

Newton Crenshaw

• Vice President of North America Oncology, Eli Lilly and Company

Marc de Garidel

• Chairman and CEO, Ipsen

Gillian Leng, MD

• Deputy Chief Executive, Director of Health and Social Care, National Institute for Health and Care Excellence

James Robinson

• President, Americas Operations, Astellas

Bruno Strigini

• President, Novartis Oncology

9:05 am – 9:55 am
Novartis Ballroom

Epigenetics and Novel Cancer Targets

The initiation and progression of cancer is controlled by both genetic and
epigenetic events. Epigenetics, the study of changes that influence how DNA
does its job, is one of the fastest-moving fields in cancer research. Expert corporate
and academic panel members will discuss the promise of epigenetics. They will
describe translating basic epigenetic research into cancer diagnostics and
therapies, emphasizing market opportunities and competitive advantages.

Moderator: Pat Fortune, PhD

• Senior Market Sector Leader, Partners Innovation

Robert Copeland, PhD

• President of Research and Chief Scientific Officer, Epizyme

Keith Dionne, PhD

• CEO, Constellation Pharmaceuticals, Inc.

Cigall Kadoch, PhD

• Assistant Professor, Dana-Farber Cancer Institute, Harvard Medical School

Jeannie Lee, MD, PhD

• Professor of Genetics, Massachusetts General Hospital

Nancy Simonian, MD

• CEO, Syros Pharmaceuticals

Johnathan Whetstine, PhD

• Tepper Family MGH Research Scholar
• Associate Professor of Medicine, Harvard Medical School

9:55 am – 10:25 am
Ipsen Foyer

Networking Break

10:25 am – 11:05 am
Novartis Ballroom

Fireside Chat: Robert Bradway, CEO, Amgen

Introduction by: Cathy Minehan

• Dean, School of Management, Simmons College

Moderator: Caroline Chen

• Reporter, Bloomberg Business

Robert Bradway

• CEO, Amgen

11:05 am – 12:00 pm
Novartis Ballroom

Immunotherapy I: Checkpoint Activation and Cancer Vaccines

Among the most promising approaches to activating therapeutic antitumor
immunity is the blockade of immune checkpoints. Checkpoint blockade, prevention
of inhibitory signaling that limits activation or function of tumor antigen-specific
T cells responses, is revolutionizing the treatment of many poor-prognosis
malignancies. Expert panelists discuss significant long-term cancer remissions,
potential cures – in some cases – and how boosting the body’s own defenses
is producing stunning results when combined with standard anticancer therapies
and other immunotherapies. They will also detail the experimental accines in
development that are designed to “wake up” the immune system so it will trigger
reliable and effective attacks on cancer cells.

Moderator: Nir Hacohen, PhD

• Immunologist, MGH Center for Immunology and Inflammatory Diseases, MGH Research Scholar
• Associate Professor, Medicine, Harvard Medical School

Thomas Daniel, MD

• Chairman, Celgene Research

Glenn Dranoff, MD

• Global Head of Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

Robert Mulroy

• President and CEO, Merrimack Pharmaceuticals

David Reese, MD

• Senior Vice President, Translational Sciences, Amgen

Scott Rodig, MD, PhD

• Associate Professor, Brigham and Women’s Hospital

Arlene Sharpe, MD, PhD

• Leader, Cancer Immunology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute
• George Fabyan Professor of Comparative Pathology, Harvard Medical School

12:00 pm – 12:30 pm
Bristol-Myers Squibb Ballroom

Lunch

12:30 pm – 1:00 pm
Bristol-Myers Squibb Ballroom

Fireside Chat: Andy Slavitt, Acting Administrator, CMS

Introduction by: David Torchiana, MD

• CEO, Partners HealthCare

Moderator: Meg Tirrell

• Biotech and Pharma Reporter, CNBC

Andy Slavitt

• Acting Administrator, CMS

1:00 pm – 1:30 pm
Bristol-Myers Squibb Ballroom

Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb

Introduction by: Thomas Lynch, MD

• CEO, Mass General Physician’s Organization

Moderator: Meg Tirrell

• Biotech and Pharma Reporter, CNBC

Giovanni Caforio, MD

• CEO, Bristol-Myers Squibb

1:40 pm – 2:10 pm
Novartis Ballroom

Fireside Chat: Patients Driving Innovation

Moderator: Nancy Snyderman, MD

• Medical Advisor, GE Healthymagination

Kathy Giusti

• Founder, Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortium

2:10 pm – 3:00 pm
Novartis Ballroom

Immunotherapy II: Cell Based Therapies

Oncology sits on the cusp of a new revolution thanks to the use of human cells as versatile
therapeutic engines. By modifying T cells to express chimeric antigen receptors (CARs) that
recognize cancer-specific antigens, our expert panelists describe how they have been able to prime
cells to recognize and kill tumor cells that would otherwise escape immune detection. They also
detail the various “living drugs” that kill cancer cells and could replace standard oncology
treatments in the future.

Moderator: David Fisher, MD, PhD

• Chief, Dermatology Service, Director, Melanoma Program, Director, Cutaneous Biology Research Center, MGH Cancer Center
• Edward Wigglesworth Professor of Dermatology, Harvard Medical School

Usman (Oz) Azam, MD

• Global Head, Cell & Gene Therapies Unit, Novartis

Mark Frohlich, MD

• Executive Vice President, Portfolio Strategy, Juno Therapeutics

Nick Leschly

• CEO, Bluebird Bio

Marcela Maus, MD, PhD

• Director of Cellular Immunotherapy, Massachusetts General Hospital
• Member of the Faculty, Harvard Medical School

Chuck Wilson, PhD

• CEO, Unum Therapeutics

3:00 pm – 3:50 pm
Novartis Ballroom

Financing Breakthrough Cancer Companies

The global market for oncology therapies is currently more than $100 billion annually, and could
reach $147 billion by the end of the decade. Panel experts discuss the most compelling
technologies, trends driving investment considerations, new models, pricing considerations and
strategies they use as leading oncology investors in both early stage and established companies.

Introduction by: Roger Kitterman

• Managing Partner, Partners Innovation

Moderator: Meg Tirrell

• Biotech and Pharma Reporter, CNBC

Jean-François Formela, MD

• Partner, Atlas Ventures

Jonathan Leff

• Partner, Deerfield Management

Amir Nashat, PhD

• Managing Partner, Polaris Partners

Christopher Viehbacher

• Managing Partner, Gurnet Point Capital

4:00 pm – 4:50 pm
Astellas Ballroom

Arms Race in Radiation

The Holy Grail of radiation therapy is to maximize the effectiveness of killing cancer
cells while minimizing the effect on neighboring tissue. Technology meets modern
cancer care with the integration of technologies that offer enormous benefits to
the cancer patient in improved quality of life and increased likelihood of
cure. Expert panelists will highlight current benefits of radiation therapies, the
increasing use of hypofractionated radiation therapy and describe future tools in
development that will have the potential to dramatically improve outcomes.

Moderator: Jay Loeffler, MD

• Chair, Radiation Oncology, Massachusetts General Hospital

Daphne Haas-Kogan, MD

• Chair, Department of Radiation Oncology, Dana-Farber Cancer Institute
• Professor of Radiation Oncology, Harvard Medical School

Theodore Hong, MD

• Director, Gastrointestinal Radiation Oncology, Massachusetts General Hospital
• Associate Professor of Radiation Oncology, Harvard Medical School

Joseph Jachinowski

• CEO, Mevion Medical Systems

Dow Wilson

• CEO, Varian Medical Systems

4:00 pm – 4:50 pm
Bristol-Myers Squibb Ballroom

Breakthrough Devices to Treat Cancer

The increasing demand for early diagnosis of cancer and the growing prevalence of
metastatic brain, lung, breast, prostate and other cancers is driving the oncology
device market. Our experts zero in on innovative technologies that will address
challenges in cancer surgery and pain management.

Moderator: Antonio Chiocca, MD, PhD

• Chairman, Neurosurgery, Brigham and Women’s Hospital
• Professor of Surgery, Harvard Medical School

Maurice Ferre, MD

• CEO, Insightec

David Lee

• CEO, Lumicell

Amy Pollack, MD

• Chief Medical Officer and Vice President of Global Medical Affairs for the Early Technologies Business Group/Minimally Invasive Technology Innovations (MITG), Medtronic

Ralph Weissleder, MD, PhD

• Director, Center for Systems Biology, Massachusetts General Hospital
• Professor, Radiology and Systems Biology, Harvard Medical School

4:00 pm – 4:50 pm
Novartis Ballroom

Study Designs to Meet the Challenges of Personalized Cancer Medicine

Cancer biology indicates that cancer is a large number of niche diseases that may be targeted
with therapies against specific molecular alterations common to multiple tumor types. This
model creates challenges for both drug development and patient care with implications for
initial indication selection and design and execution of clinical trials – from first in human
through post marketing studies. Among the topics the panel will address:
• The availability of biomarkers to stratify trials, select patients and monitor drug response can improve
both trial speed and cost, as well as enable development of companion diagnostics but at the same time
present more complex validation requirements.
• Design of trials using surrogate end points holds great promise but validation of such endpoints is a
regulatory challenge. Adaptive trial designs for dose response, pK/PD and efficacy hold promise but
adoption of such approaches has been slow.
• Cancer immunotherapies create a significant opportunity for development of combination therapies
but the cost of acquiring the approved drug can significantly increase the cost of clinical trials. This may
necessitate new approaches to late preclinical development as well as biomarkers that are early and
accurate indicators of drug response for incorporation in the clinical trial in Phase I/II.
• The cost of current and next generation cancer drugs will require measuring clinical and econometric
outcomes in order to justify reimbursement. This may mandate larger post marketing clinical studies,
including observational trials

Moderator: Gideon Gil

• Managing Editor, STAT

Julia Beaver, MD

• Acting Clinical Team Leader, Division of Oncology Products 1, CDER, FDA

Maria Koehler, MD, PhD

• Vice President, Strategy, Innovation and Collaborations, Pfizer Oncology Business Unit

Deborah Schrag, MD

• Chief, Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute
• Professor of Medicine, Harvard Medical School

Mike Vasconcelles, MD

• CMO, Unum Therapeutics

4:00 pm – 4:50 pm
Takeda Ballroom

Surviving Cancer: New Realities, New Needs

Extraordinary treatment advances have turned many cancers from apparent death sentences
into manageable chronic illnesses with extraordinary consequences for the entire health
care system. In the United States, there are approximately 14 million cancer survivors, up from
just three million four decades ago. Those survivors have unique care requirements, that will
put enormous stress on the system — calling out for new technology solutions. The panel will
discuss requirements technologies and approaches that can help monitor, guide, and connect
patients.

Introduction by: Trung Do

• Executive Director, Business Development, Partners Innovation

Moderator: Tim Ferris, MD

• Senior Vice President of Population Health Management, Partners HealthCare

Jani Ahonala

• CEO, Noona Healthcare

Don Dizon, MD

• Clinical Co-Director, Gynecologic Oncology, Founder and Director, The Oncology Sexual Health Clinic, Massachusetts General Hospital
• Associate Professor of Medicine, Harvard Medical School

Ann Partridge, MD

• Director, Adult Survivorship Program, Program for Young Women with Breast Cancer, Dana-Farber Cancer Institute
• Associate Professor of Medicine, Harvard Medical School

Claire Thom

• Senior Vice President, Global Oncology Development, Astellas

5:00 pm – 6:30 pm
General Electric Foyer

Attendee Reception

WEDNESDAY, APRIL 27, 2016

 

7:30 am – 8:30 am
Ipsen Foyer

Continental Breakfast

8:10 am – 9:00 am
Novartis Ballroom

Combination Cancer Therapies: Drug Resistance and Therapeutic Index

Study Designs to Meet the Challenges of Personalized Cancer Medicine Game changing modern
cancer therapies—immunotherapies and targeted therapies, among others—do not by themselves
meet the needs of many patients who require alternative strategies to achieve optimal therapeutic
benefit. Panel experts will describe combining these therapies with other drugs, challenges and the
path forward.

Moderator: Jens Eckstein, PhD

• President, SR One

Kenneth Anderson, MD

• Director, Jerome Lipper Multiple Myeloma Center, Kraft Family Professor of Medicine, Harvard Medical School

Jeffrey Engelman, MD, PhD

• Director, Thoracic Oncology and Director, Molecular Therapeutics, Medical Oncology, Massachusetts General Hospital
• Laurel Schwartz Associate Professor of Medicine, Harvard Medical School

Jamie Freedman, MD, PhD

• Senior Vice President, Global Clinical Development, Medimmune

David Schenkein, MD

• CEO, Agios Pharmaceuticals

William Sellers, MD

• Vice President and Global Head of Oncology, Novartis Institutes for BioMedical Research

9:00 am – 9:40 am
Novartis Ballroom

Fireside Chat: Joseph Jimenez, CEO, Novartis

Moderator: Gregg Meyer, MD

• Chief Clinical Officer, Partners Healthcare System

Joseph Jimenez

• CEO, Novartis

9:40 am – 10:30 am
Novartis Ballroom

Cancer Diagnostics: New Uses, New Reimbursements?

Advances in genetics, genomics and proteomics are driving advances in identifying and treating
disease. Use of genetic testing and molecular diagnostics is rapidly expanding in clinical practice,
creating a new, personalized approach to medicine. Panelists describe key new technologies and
how they will be fully integrated into the delivery of care.

Moderator: Jeffrey Golden, MD

• Chair of Pathology, Brigham and Women’s Hospital
• Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Helmy Eltoukhy, PhD

• CEO, Guardant Health, Inc.

Marc Grodman, MD

John Iafrate, MD, PhD

• Associate in Pathology, Medical Director, Center for Integrated Diagnostics, Massachusetts General Hospital
• Professor of Pathology, Harvard Medical School

Neal Lindeman, MD

• Associate Pathologist, Brigham and Women’s Hospital
• Associate Professor, Pathology, Harvard Medical School

Michael Pellini, MD

• CEO, Foundation Medicine

Risa Stack, PhD

• General Manager, New Business Creation, GE Ventures

10:30 am – 11:20 am
Novartis Ballroom

New Philanthropy: Patients Driving Innovation

Philanthropy’s role in driving improved cancer care has evolved rapidly over the
last decade. Disease foundations have become active in nearly every phase of the
care spectrum supporting innovations in the lab, clinic, patient engagement, and
regulatory approval among others. Senior philanthropic leaders will describe how
the foundation community is redefining roles and finding new ways to help
patients as they seek to drive breakthroughs in understanding and care.

Moderator: Mallika Marshall, MD

• Health Reporter, WBZ-TV/CBS Boston

Louis DeGennaro, PhD

• President and CEO, The Leukemia & Lymphoma Society

Judy Salerno, MD

• President and CEO, Susan G. Komen for the Cure

Scott Sperling

• Co-President, Thomas H. Lee Partners

Billy Starr

• Founder and Executive Director, Pan-Mass Challenge

11:25 am – 12:25 pm
Novartis Ballroom

Disruptive Dozen

Cancer faculty from the Brigham and Women’s Hospital, Massachusetts General
Hospital, and Dana-Farber Cancer Institute nominated dozens of technologies that
will have the greatest impact on cancer care in the next decade, and then compiled
a ranking of the 12 most disruptive technologies. A panel of experts will announce
and discuss each of the technologies chosen. This intriguing, informative and fun
session will let you in on how the experts view the future in their field.

Monica Bertagnolli, MD

• Chief, Division of Surgical Oncology, Brigham and Women’s Hospital
• Professor of Surgery, Harvard Medical School

Daniel Haber, MD, PhD

• Director, MGH Cancer Center
• Kurt J. Isselbacher /Peter D. Schwartz Professor of Oncology, Harvard Medical School

12:25 pm – 12:45 pm
Ipsen Foyer

Boxed Lunches Available

12:25 pm – 12:35 pm
Novartis Ballroom

Forum Closing

SOURCE

From: Kari Watson <contact@macbiocom.ccsend.com> on behalf of Kari Watson <wmif@macbiocom.com>

Reply-To: <wmif@macbiocom.com>

Date: Wednesday, April 13, 2016 at 10:59 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Medical Innovation Forum to Feature Innovations Enhancing Patient Care

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,040 other subscribers

• Recent Posts

  • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
  • In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
  • Top VC Investors in AI / Health AI in 2026 May 26, 2026
  • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
  • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
  • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
  • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026

• Archives

  Archives Select Month June 2026  (3) May 2026  (1) January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (234)    An executive’s guide to AI  (11)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (116)    Artificial Intelligence Applications in Health Care  (126)       Artificial Intelligence in CANCER  (39)       Artificial Intelligence in Health Care – Tools & Innovations  (75)    Artificial Intelligence in Medicine – Application for Diagnosis  (69)       Artificial intelligence applications for cardiology  (31)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (6)       Deep Learning in Pathology  (18)    Artificial Intelligence in Medicine – Applications in Therapeutics  (66)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (71)       Deep Learning  (25)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (5) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (15) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (131)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (108)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (411)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,123)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (84)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (3)       TP53 – Germline mutations  (8)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (12)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (131) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (6) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (3) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (238) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (21) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (487) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (158)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (71) FDA Regulatory Affairs  (358)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (232) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (203) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (2) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (47) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (138) Healthcare Reform  (117)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (26)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (140)    Cancer-Immune Interactions  (30)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (134)    CAR-T  (14)    combination immunotherapies.  (14)    Efficacy of Anti-Tumor T Cells  (14)    Engineering Better T Cells  (9)    Immune Engineering  (17)    Immune Modulatory  (15)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (16)    NK Cell-Based Cancer Immunotherapy  (19)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (84)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (120) International Global Work in Pharmaceutical  (190) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (316)    Albany Medical Center Prize in Medicine and Biomedical Research  (2)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (10)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (5)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (4)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (29)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (14) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (22)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (736)    Longevity  (3)    New Drug Approval  (5)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (31) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (109)    Rapid automation of plasma protein pools  (17) Pharmaceutical Drug Discovery  (201)    Drug Development Process  (56)       Drug Discovery Chemistry  (30)    drug repurposing  (10) Pharmaceutical Industry Competitive Intelligence  (343)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (44) Pharmaceutical R&D Investment  (299) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (159) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (204)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (197)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa